Benign Prostatic Hyperplasia Treatment Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Minimal Invasive Surgery, Invasive Surgery), By Procedure (Transurethral Resection of the Prostate, Prostate Laser Surgery, Transurethral Microwave Thermotherapy, Transurethral Needle Ablation of the Prostate, Prostatic Urethral Lift, Water Vapor Therapy, Others), By Product (Resectoscopes, Urology Laser, Radiofrequency Ablation, Electrodes, Catheters, Prostatic Stents, Implants, Others), By End use (Hospitals & Clinics, Research and Manufacturing, others), By Region and Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 13.06 Billion
CAGR (2026-2031)	4.71%
Fastest Growing Segment	Minimal Invasive Surgery
Largest Market	North America
Market Size (2031)	USD 17.21 Billion

Market Overview

The Global Benign Prostatic Hyperplasia Treatment Devices Market will grow from USD 13.06 Billion in 2025 to USD 17.21 Billion by 2031 at a 4.71% CAGR. Benign Prostatic Hyperplasia (BPH) treatment devices encompass a diverse range of minimally invasive and surgical technologies, including laser ablation systems, electrosurgical units, and prostatic urethral lift implants, designed to alleviate lower urinary tract symptoms associated with non-malignant prostate enlargement. The global market is primarily supported by the rapid expansion of the aging male demographic and a distinct clinical preference for minimally invasive surgical therapies that offer shorter recovery times compared to traditional interventions. These fundamental drivers are separate from transient technological trends, ensuring a sustained demand for effective therapeutic solutions.

However, a significant challenge impeding market expansion is the complex reimbursement landscape for novel device technologies, which can restrict patient access and limit adoption in cost-constrained healthcare systems. Illustrating the scale of the condition, according to the American Urological Association, in 2024, the prevalence of Benign Prostatic Hyperplasia among men aged 65 and older was reported to be approximately 29% to 35%. This substantial prevalence rate underscores the critical and growing necessity for accessible medical interventions within the sector.

Key Market Drivers

Technological advancements in robotic-assisted systems and laser ablation are fundamentally reshaping the market by prioritizing precision and reduced recovery times. These innovations are rapidly displacing traditional transurethral resections, as clinicians and patients increasingly opt for automated, tissue-sparing modalities that minimize sexual side effects and hospitalization. This shift toward advanced procedural efficiency is evident in the financial performance of emerging leaders in the space. According to PROCEPT BioRobotics, October 2024, in the 'Third Quarter 2024 Financial Results', total revenue increased by 66% year-over-year to $58.4 million, a growth trajectory largely attributed to the robust adoption of its Aquablation robotic systems. Such acceleration highlights the sector's responsiveness to novel mechanical and robotic solutions that offer consistent, minimally invasive clinical outcomes.

The rising global geriatric population acts as the primary demographic catalyst sustaining long-term market expansion, given the direct correlation between aging and the onset of prostate enlargement symptoms. As life expectancy increases worldwide, the volume of men susceptible to lower urinary tract symptoms is expanding, necessitating scalable and effective medical interventions. According to the United Nations Population Fund, July 2024, in the '2024 State of World Population Report', the percentage of the global population aged 65 and older reached 10.3% in 2024, representing a significant structural shift in potential patient density. This demographic pressure translates into tangible commercial gains for established device manufacturers. According to Boston Scientific, in February 2025, the company's Urology segment achieved a 12.0% increase in reported net sales for the full year 2024, confirming the growing procedural demand within this expanding elderly cohort.

Download Free Sample Report

Key Market Challenges

The complex reimbursement landscape for novel device technologies significantly hampers the growth of the Global Benign Prostatic Hyperplasia Treatment Devices Market by creating financial barriers to adoption for healthcare providers. When new device technologies are introduced, they often lack established billing codes or favorable coverage policies, forcing medical facilities to absorb costs or rely on uncertain payment models. This economic uncertainty discourages hospitals and urology practices from investing in capital-intensive equipment, leading them to favor established, fully reimbursed procedures despite the potential clinical benefits of newer alternatives.

Consequently, urologists face declining margins that further restrict their ability to integrate emerging therapeutic options. According to the American Urological Association, in 2024, the Centers for Medicare & Medicaid Services finalized a payment rule for the subsequent year that decreased the Medicare conversion factor by approximately 2.83 percent. This reduction in reimbursement rates exacerbates the financial pressure on providers, directly limiting their capacity to adopt novel BPH treatment devices and stalling overall market expansion in cost-sensitive healthcare environments.

Key Market Trends

The market entry of temporary implantable nitinol devices represents a distinct shift toward non-permanent, mechanical reshaping of the prostatic urethra, differentiating itself from traditional permanent stenting or ablative methods. These devices, such as the iTind system, are designed to remodel the bladder neck and preserve sexual function by avoiding thermal damage or permanent foreign bodies, directly addressing a critical patient quality-of-life priority. This innovative approach is gaining significant commercial traction as manufacturers focus on expanding availability in key geographic regions to meet the demand for ejaculation-preserving options. According to Olympus Corporation, August 2024, in the 'Consolidated Financial Results for the 1st Quarter for Fiscal Year 2025', revenue in North America increased by 32% year-over-year, a performance partially attributed to the company's strategic initiative to expand its leadership in the sector through the market development of its iTind temporary placement device.

Concurrently, the widespread commercialization of water vapor thermal therapy is establishing a new standard for office-based interventions, utilizing convective steam energy to treat hyperplasia efficiently. This modality distinguishes itself from robotic or laser enucleation by delivering sterile water vapor into the prostate tissue, which rapidly disperses thermal energy to induce cell death without the need for complex surgical infrastructure. The rapid adoption of this technology is fueled by its ability to offer durable symptom relief with minimal procedure time, driving substantial growth within the urology portfolios of major device companies. According to Boston Scientific, October 2024, in the 'Third Quarter 2024 Financial Results', the company's Urology segment reported a 10.3% increase in net sales compared to the prior year period, a growth trajectory supported by the double-digit sales expansion of its prostate health franchise, including the Rezūm Water Vapor Therapy system.

Segmental Insights

Minimally Invasive Surgery represents the fastest expanding segment within the Global Benign Prostatic Hyperplasia Treatment Devices Market due to a marked shift toward outpatient care models. This growth is primarily driven by the ability of these procedures to reduce hospital stays and minimize post-operative complications compared to traditional surgical interventions. Consequently, patient demand has surged for treatments that offer rapid recovery times. Furthermore, consistent product approvals by regulatory authorities such as the US Food and Drug Administration have validated the safety of these devices, thereby accelerating clinical adoption across major healthcare facilities.

Regional Insights

North America maintains a leading position in the Benign Prostatic Hyperplasia Treatment Devices market due to a well-established healthcare infrastructure and a growing geriatric population susceptible to urological conditions. This market strength is supported by favorable reimbursement policies managed by institutions such as the Centers for Medicare and Medicaid Services, which improve treatment affordability for patients. Additionally, the rapid commercialization of devices is enabled by clear regulatory pathways defined by the U.S. Food and Drug Administration. These factors, combined with a strong preference for minimally invasive procedures, ensure the region remains the central hub for market activity.

Recent Developments

• In December 2025, ProVerum Limited obtained approval from the U.S. Food and Drug Administration (FDA) for its ProVee System, a minimally invasive device for treating benign prostatic hyperplasia (BPH). The regulatory decision was supported by data from the ProVIDE clinical study, which demonstrated that the device effectively relieved lower urinary tract symptoms and improved urinary flow without causing serious device-related adverse events. The ProVee System, functioning as a prostatic urethral expander, offered a new mechanical solution for managing enlarged prostates. This milestone allowed the company to introduce the technology to the U.S. market as a therapeutic option for patients seeking symptom relief.
• In December 2025, Zenflow, Inc. secured approval from the U.S. Food and Drug Administration (FDA) for its Spring Implant and Delivery System to treat symptoms associated with benign prostatic hyperplasia (BPH). This approval was based on results from the pivotal BREEZE clinical trial, which indicated that the device provided significant symptom improvement while preserving sexual function. The system was designed as a first-line interventional therapy, utilizing a small, spring-like implant to prop open the urethra and alleviate obstruction caused by an enlarged prostate. The regulatory clearance marked the company's transition into the commercialization phase for this outpatient treatment device.
• In August 2024, Procept BioRobotics Corporation received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its HYDROS Robotic System. This next-generation platform utilized artificial intelligence to facilitate advanced image interpretation and surgical planning for Aquablation therapy, a waterjet-based treatment for benign prostatic hyperplasia (BPH). The system was developed to improve workflow efficiency through an integrated ultrasound and digital cystoscope, streamlining the procedural setup for broader adoption in hospitals. The company indicated that the clearance would enable a full market release of the robotic system to support the delivery of automated BPH therapy.
• In April 2024, Teleflex Incorporated announced the full commercial launch of its UroLift 2 System with Advanced Tissue Control (ATC) in the United States. This unified platform was designed to treat benign prostatic hyperplasia (BPH) in patients with various prostate types, including those with lateral and median lobe hyperplasia and prostate volumes of up to 100 grams. The system featured enhanced design elements, such as tissue control wings and laser-etched needle markers, to improve targeting accuracy and tissue manipulation during the procedure. The launch aimed to provide urologists with greater confidence and customization capabilities for minimally invasive treatments.

Key Market Players

• Boston Scientific Corporation
• Olympus America
• Endo Pharmaceuticals Inc.
• biolitec AG
• Medifocus Inc.
• Cook Medical
• Teleflex Incorporated
• Urotronic
• Coloplast Corp
• Richard Wolf GmbH
• PROCEPT BioRobotics Corporation

By Treatment	By Procedure	By Product	By End use	By Region
Minimal Invasive Surgery Invasive Surgery	Transurethral Resection of the Prostate Prostate Laser Surgery Transurethral Microwave Thermotherapy Transurethral Needle Ablation of the Prostate Prostatic Urethral Lift Water Vapor Therapy Others	Resectoscopes Urology Laser Radiofrequency Ablation Electrodes Catheters Prostatic Stents Implants Others	Hospitals & Clinics Research and Manufacturing others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Benign Prostatic Hyperplasia Treatment Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Benign Prostatic Hyperplasia Treatment Devices Market, By Treatment:

• Minimal Invasive Surgery
• Invasive Surgery

• Benign Prostatic Hyperplasia Treatment Devices Market, By Procedure:

• Transurethral Resection of the Prostate
• Prostate Laser Surgery
• Transurethral Microwave Thermotherapy
• Transurethral Needle Ablation of the Prostate
• Prostatic Urethral Lift
• Water Vapor Therapy
• Others

• Benign Prostatic Hyperplasia Treatment Devices Market, By Product:

• Resectoscopes
• Urology Laser
• Radiofrequency Ablation
• Electrodes
• Catheters
• Prostatic Stents
• Implants
• Others

• Benign Prostatic Hyperplasia Treatment Devices Market, By End use:

• Hospitals & Clinics
• Research and Manufacturing
• others

• Benign Prostatic Hyperplasia Treatment Devices Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE